Prediction of future tau accumulation and cognitive decline in Down Syndrome using plasma biomarkers

Abstract

Background: Plasma biomarkers of Alzheimer's disease (AD) could improve the prognostic evaluation of individuals with Down syndrome (DS) in both clinical practice and trials. In this study, we aimed to identify plasma biomarkers that best predict changes in AD‐related tau pathology and cognitive decline in DS.